velcade

Bortezonib ( velcade ) is the first proteasome inhibitor that has entered clinical trial .

波替单抗（万珂）是第一个进入临床试验的蛋白酶体抑制剂。

Compared to traditional chemotherapy , what is the advantage of Velcade ?

您认为含万珂的化疗方案与传统方案相比，有什么优势？

Nursing Care for Refractory Multiple Myeloma Cases Treated with Velcade and Dexamethasone

万珂联合地塞米松治疗难治性多发性骨髓瘤患者的护理

The Protective Effects of Edaravone and Velcade on Ischemia-reperfusion Injury in Rats Brain

依达拉奉和万珂对大鼠脑缺血再灌注损伤保护作用机制的研究

How many cycles , in average , of Velcade do you give to your MM patients ?

您使用过的万珂平均疗程数是多少？

How many percentage of MM patients in your department received Velcade based regimens in the half past year ?

在过去半年治疗多发性骨髓瘤使用的含万珂的化疗方案占所有方案的百分比是多少？

If a newly-diagnosed MM young patient receive Velcade regimen as induction before ASCT , What is your most preferred combination regimen ?

新诊断的年轻骨髓瘤患者自体移植前如果采用万珂诱导治疗，您首选的联合方案是？